Opinion
Video
Author(s):
Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.
OncLive’s May Roundup of Key FDA Approvals in Oncology
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
FDA Advisory Committee Recommends Approval of Shield Blood Test for CRC Detection in Average-Risk Adults
Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
Pellini Discusses Immunotherapies and Current Limitations of ctDNA in Perioperative NSCLC
Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Lorlatinib Yields Longest Reported PFS in Advanced NSCLC
Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma